Now showing items 1-1 of 1

    • First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study 

      Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Serra, O.; Vera, R.; Casado, Enrique; Jorge, Monica; Escudero, P.; Bosch, Carlos; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Martínez-Marín, V.; Maurel, Joan (Cancer Research UK, 2014)
      Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the ...